Chinanews.com, August 31. According to a report by the US Chinese website, the US Food and Drug Administration (FDA) Director Hahn said that the entire federal approval process may be bypassed in order to supply the new crown virus vaccine as soon as possible. He said that if the benefits outweigh the risks, an emergency authorization can be issued before completing the third phase of clinical trials. He also said that the move was not due to the government's pressure for rapid vaccine development.

Data map: On August 24, local time, a children's toy chain store in Long Island, New York, USA, took restrictive measures in response to the epidemic, while only five customers were shopping in the store. Photo by China News Agency reporter Liao Pan

　　According to reports, Hahn told the Financial Times: “(Vaccine developers) have the right to apply for authorization or approval, and we will make a ruling on their application.” “If they do this before the end of the third phase (clinical trial), We may think it is appropriate; we (also) may find it inappropriate, and we will make a decision."

　　Previously, although some health officials were worried that the clinical trial data was too weak, the FDA still urgently approved the use of restorative plasma to treat hospitalized new crown patients.

　　Hahn said he will not rush to approve the vaccine just to please US President Trump. Trump once accused the FDA of trying to slow down the approval of new coronavirus vaccines and therapies without any evidence, in order to disadvantage it politically.

　　"We are facing the combination of the new crown pandemic and the political season. We will have to overcome this and stick to our core principles." Hahn said, "This will be a decision based on science, medicine, and data." "It won't be. A political decision."

　　He said that emergency authorization can be used to safely provide vaccines to certain groups before the clinical trials are completed. "Our emergency use authorization is different from full approval." Hahn said, "The legal, medical and scientific standard is that in a public health emergency, the benefits outweigh the risks."

　　Last week, the “Financial Times” reported that the Trump administration is considering issuing an emergency use authorization to an experimental new coronavirus vaccine developed by Oxford University and AstraZeneca in the UK before the presidential election. At the time, a spokesperson for the US Department of Health said that any report about the emergency authorization of vaccines before the election was "absolutely wrong." AstraZeneca said it has not discussed the move with the US government.